Diffusion Pharmaceuticals Inc. (DFFN) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Charlottesville, VA, アメリカ. 現CEOは Robert J. Cobuzzi Jr.,.
DFFN を有する IPO日 2008-05-23, 13 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $8.98M.
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.
